)
Visual
test
CervoMed
CervoMed (CRVO) investor relations material
CervoMed Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary7 Nov, 2025
Executive summary
Clinical-stage biotech focused on age-related brain disorders, with lead candidate neflamapimod targeting neuroinflammation and neurodegeneration in DLB and other indications.
Completed Phase 2b RewinD-LB Trial in DLB, showing statistically significant and durable clinical and biomarker improvements, and aligned with FDA for a planned Phase 3 trial.
Preparing for a global pivotal Phase 3 trial in DLB in the second half of 2026, with additional Phase 2a data in FTD and stroke recovery expected in 2026.
Appointed new Chief Commercial and Business Officer and added a new Board member.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $27.3 million as of September 30, 2025, down from $38.9 million at December 31, 2024.
Net loss was $18.9 million for the nine months ended September 30, 2025, compared to $9.6 million for the same period in 2024.
Grant revenue recognized was $4.0 million for the nine months ended September 30, 2025, down from $7.6 million in 2024.
R&D expenses increased 37% year-over-year to $16.0 million; general and administrative expenses rose 16% to $8.0 million.
Net loss for Q3 2025 was $7.7 million, compared to $4.8 million in Q3 2024.
Outlook and guidance
Cash on hand is expected to fund operations into Q3 2026 based on current plans, but substantial doubt exists about ability to continue as a going concern without additional funding.
Plans to initiate a global Phase 3 trial in DLB in the second half of 2026, pending additional funding.
Will continue to seek additional financing through equity, debt, or strategic arrangements.
Quantify impact of NIA grant's remaining 2% uncertainty
Rationale for Phase 3 DLB patient exclusion criteria
Update on expense account control weakness remediation
Explain the Phase 3 DLB patient enrichment strategy
How will CervoMed fund Phase 3 DLB trial?
What was the December 2024 drug product issue?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income.
Next CervoMed earnings date
Q4 202519 Mar, 2026
CervoMed
Next CervoMed earnings date
Q4 202519 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
CervoMed Inc. is a biotechnology company specializing in the development and commercialization of treatments for age-related neurologic disorders. The company’s key focus is on addressing synaptic dysfunction, a critical factor in neurodegenerative diseases. Its lead product candidate, neflamapimod, is an orally administered small molecule designed to treat conditions such as dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia by reversing synaptic dysfunction. CervoMed also has additional programs targeting central nervous system disorders in earlier stages of development. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage